ABSTRACT
Cardiac amyloidosis is a restrictive cardiomyopathy caused by extracellular deposition of misfolded amyloid fibrils. Although it was considered a rare disease until recently, emerging data suggests that a significant portion of patients with heart failure with preserved ejection fraction and severe aortic stenosis have underlying cardiac amyloidosis. Radionuclide imaging with bone seeking agents is a non-invasive method that plays an important for the diagnosis of ATTR cardiac amyloidosis. Increased myocardial uptake of bone seeking agents is a highly accurate diagnostic finding for ATTR cardiac amyloidosis, provided that AL amyloidosis is excluded. This review article discusses the fundamental principles of radionuclide cardiac imaging for the diagnosis of cardiac amyloidosis, its current role in light of recent literature, and future perspectives in this regard.